Drug maker Bafna Pharmaceuticals today said it has got approval from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for its product -- Simvastatin in the strength of 10 mg.
"The company’s product Simvastatin has got approval from MHRA, UK on December 29, 2009," Bafna Pharma said in a filing to the Bombay Stock Exchange (BSE).
The company did not disclose further details about the drug. Simvastatin is an anti—cholesterol product.
Shares of Bafna Pharmaceuticals settled at Rs 34.75, up 2.21 per cent on the BSE today.
